A Retrospective Sero-Surveillance Study for Antibodies Against
Tick-Borne Encephalitis Virus in Norway

J 2025

A Retrospective Sero-Surveillance Study for Antibodies Against Tick-Borne Encephalitis Virus in Norway

LAMSAL, Alaka; Katrine Mork PAULSEN; Maria Juul DIEKMANN; Olav HUNGNES; Kristian ALFSNES et al.

Základní údaje

Originální název

A Retrospective Sero-Surveillance Study for Antibodies Against Tick-Borne Encephalitis Virus in Norway

Autoři

Vydání

Viruses, Basel, MDPI, 2025, 1999-4915

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10607 Virology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.500 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

tick-borne encephalitis virus; TBEV prevalence; Norway; central nervous system infections; seroprevalence study

Štítky

14314010, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 12. 2025 10:37, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Tick-borne encephalitis virus (TBEV) is an emerging pathogen that initially causes flu-like symptoms and can progress to central nervous system (CNS) infections. Tick-borne encephalitis (TBE) is an endemic disease in southern coastal counties with regular human cases, while the causative agent, TBEV, is prevalent in ticks in most of the coastal regions of Norway. This study was aimed to understand TBEV infection status across Norway including both TBE endemic and non-endemic areas. For this, we analyzed a total of 1940 residual serum samples from 19 counties of Norway (as of 2016). The samples were initially screened by ELISA, followed by virus neutralization tests for TBEV confirmation. We found a similar TBEV seroprevalence of 1.7% in TBE endemic and 1.6% in non-endemic areas. Since TBE cases are only reported from endemic regions, our findings suggest a potential subclinical or asymptomatic infection and underdiagnosis in non-endemic areas. Notably, only 43% of the ELISA-positive samples were confirmed by virus neutralization tests indicating that not all ELISA positives are true TBEV infections. Additionally, 137 samples of patients presenting with symptoms of CNS infections from a non-endemic area were included. Of these samples, 11 ELISA-positive samples were analyzed for cross-reactivity among flaviviruses. Cross-reactivity was detected with Dengue virus, West Nile Virus, and non-specific reactions. This underscores the importance of using multiple diagnostic tests to confirm TBEV infections. None of the patients with CNS infection was found to be TBE positive, and in the whole cohort, we found a low TBEV seroprevalence of 0.7%.

Citovat

LAMSAL, Alaka; Katrine Mork PAULSEN; Maria Juul DIEKMANN; Olav HUNGNES; Kristian ALFSNES; Else QUIST-PAULSEN; Daniel RŮŽEK; Jiri SALAT; Petra STRAKOVA; Karen Angeliki KROGFELT; Arnulf SOLENG; Rose VIKSE a Ashild K. ANDREASSEN. A Retrospective Sero-Surveillance Study for Antibodies Against Tick-Borne Encephalitis Virus in Norway. Viruses. Basel: MDPI, 2025, roč. 17, č. 3, s. 291-300. ISSN 1999-4915. Dostupné z: https://doi.org/10.3390/v17030291.

@article{2536913,
   author = {Lamsal, Alaka and Paulsen, Katrine Mork and Diekmann, Maria Juul and Hungnes, Olav and Alfsnes, Kristian and QuistandPaulsen, Else and Růžek, Daniel and Salat, Jiri and Strakova, Petra and Krogfelt, Karen Angeliki and Soleng, Arnulf and Vikse, Rose and Andreassen, Ashild K.},
   article_location = {Basel},
   article_number = {3},
   doi = {https://doi.org/10.3390/v17030291},
   keywords = {tick-borne encephalitis virus; TBEV prevalence; Norway; central nervous system infections; seroprevalence study},
   language = {eng},
   issn = {1999-4915},
   journal = {Viruses},
   title = {A Retrospective Sero-Surveillance Study for Antibodies Against Tick-Borne Encephalitis Virus in Norway},
   url = {https://www.mdpi.com/1999-4915/17/3/291},
   volume = {17},
   year = {2025}
}

TY  - JOUR
ID  - 2536913
AU  - Lamsal, Alaka - Paulsen, Katrine Mork - Diekmann, Maria Juul - Hungnes, Olav - Alfsnes, Kristian - Quist-Paulsen, Else - Růžek, Daniel - Salat, Jiri - Strakova, Petra - Krogfelt, Karen Angeliki - Soleng, Arnulf - Vikse, Rose - Andreassen, Ashild K.
PY  - 2025
TI  - A Retrospective Sero-Surveillance Study for Antibodies Against Tick-Borne Encephalitis Virus in Norway
JF  - Viruses
VL  - 17
IS  - 3
SP  - 291
EP  - 291
PB  - MDPI
SN  - 19994915
KW  - tick-borne encephalitis virus
KW  - TBEV prevalence
KW  - Norway
KW  - central nervous system infections
KW  - seroprevalence study
UR  - https://www.mdpi.com/1999-4915/17/3/291
N2  - Tick-borne encephalitis virus (TBEV) is an emerging pathogen that initially causes flu-like symptoms and can progress to central nervous system (CNS) infections. Tick-borne encephalitis (TBE) is an endemic disease in southern coastal counties with regular human cases, while the causative agent, TBEV, is prevalent in ticks in most of the coastal regions of Norway. This study was aimed to understand TBEV infection status across Norway including both TBE endemic and non-endemic areas. For this, we analyzed a total of 1940 residual serum samples from 19 counties of Norway (as of 2016). The samples were initially screened by ELISA, followed by virus neutralization tests for TBEV confirmation. We found a similar TBEV seroprevalence of 1.7% in TBE endemic and 1.6% in non-endemic areas. Since TBE cases are only reported from endemic regions, our findings suggest a potential subclinical or asymptomatic infection and underdiagnosis in non-endemic areas. Notably, only 43% of the ELISA-positive samples were confirmed by virus neutralization tests indicating that not all ELISA positives are true TBEV infections. Additionally, 137 samples of patients presenting with symptoms of CNS infections from a non-endemic area were included. Of these samples, 11 ELISA-positive samples were analyzed for cross-reactivity among flaviviruses. Cross-reactivity was detected with Dengue virus, West Nile Virus, and non-specific reactions. This underscores the importance of using multiple diagnostic tests to confirm TBEV infections. None of the patients with CNS infection was found to be TBE positive, and in the whole cohort, we found a low TBEV seroprevalence of 0.7%.
ER  -

LAMSAL, Alaka; Katrine Mork PAULSEN; Maria Juul DIEKMANN; Olav HUNGNES; Kristian ALFSNES; Else QUIST-PAULSEN; Daniel RŮŽEK; Jiri SALAT; Petra STRAKOVA; Karen Angeliki KROGFELT; Arnulf SOLENG; Rose VIKSE a Ashild K. ANDREASSEN. A Retrospective Sero-Surveillance Study for Antibodies Against Tick-Borne Encephalitis Virus in Norway. \textit{Viruses}. Basel: MDPI, 2025, roč.~17, č.~3, s.~291-300. ISSN~1999-4915. Dostupné z: https://doi.org/10.3390/v17030291.

Přehled o publikaci